


L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS
 RN 137071-32-0 REGISTRY
 CN 15,19-Epoxy-3H-pyrido[2,1-c] [1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone, 3-[(1E)-2-[(1R,3R,4S)-4-chloro-3-methoxycyclohexyl]-1-methylethenyl]-8-ethyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-14,16-dimethoxy-4,10,12,18-tetramethyl-, (3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 15,19-Epoxy-3H-pyrido[2,1-c] [1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone, 3-[2-(4-chloro-3-methoxycyclohexyl)-1-methylethenyl]-8-ethyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-14,16-dimethoxy-4,10,12,18-tetramethyl-, [3S-[3R*[E(1S*,3S*,4R*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-
 OTHER NAMES:
 CN 33-*epi*-Chloro-33-desoxyascomycin
 CN Elidel
 CN Pimecrolimus
 CN SDZ-ASM 981
 FS STEREOSEARCH
 MF C43 H68 Cl N O11
 SR CA
 LC STN Files: ADISNEWS, BIOSIS, BIOTECHNO, CA, CAPLUS, CIN, DIOGENES, DRUGNL, DRUGPAT, DRUGUPDATES, EMBASE, IPA, MRCK*, PHAR, PROMT, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)

Absolute stereochemistry.
 Double bond geometry as described by E or Z.


PAGE 1-A



PAGE 1-B

O

PAGE 2-A



REGISTRY COPYRIGHT 2002 ACS
RN 104987-12-4 REGISTRY

CN 15,19-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone, 8-ethyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-[(1E) -2- [(1R,3R,4R) -4-hydroxy-3-methoxycyclohexyl] -1-methylethenyl] -14,16-dimethoxy-4,10,12,18-tetramethyl-, (3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 15,19-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone, 8-ethyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-, [3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-

OTHER NAMES:

CN Ascomycin

CN FK 520

CN FR 520

CN FR 900520

CN Immunomycin

CN L 683590

FS STEREOSEARCH

DR 11011-38-4, 159430-76-9, 126340-36-1, 133876-12-7, 136457-58-4,
137767-75-0, 148400-02-6

MF C43 H69 N O12


SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT,
CEN, CHEMCATS, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IFICDB, IFIUDB,
MEDLINE, NAPRALERT, PHAR, PROMT, RTECS*, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.

Double bond geometry as described by E or Z.


PAGE 1-A




PAGE 1-B




PAGE 2-A



PAGE 2-B





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

236 REFERENCES IN FILE CA (1962 TO DATE)

37 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

236 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=>

L3 ANSWER 1 OF 6 JAPIO COPYRIGHT 2002 JPO
AN 1998-251137 -JAPIO
TI INHIBITOR AGAINST PHOTOSENSITIVITY
IN SATO ETSUHISA; OOSAKA TOSHIE
PA ADVANCED SUKIN RES KENKYUSHO:KK
PI JP 10251137 A 19980922 Heisei
AI JP 1997-79164 (JP09079164 Heisei) 19970314
PRAI JP 1997-79164 19970314
SO PATENT ABSTRACTS OF JAPAN (CD-ROM), Unexamined Applications, Vol. 1998
IC ICM A61K007-48
ICS A61K007-40; A61K009-06; A61K031-71; A61K038-00
ICA C07H007-06
AB PROBLEM TO BE SOLVED: To obtain a preparation having an excellent inhibitor activity against photosensitivity especially when administered externally (percutaneously), by including a specific compound having an immunosuppressive activity as the active ingredient.
SOLUTION: This preparation for external (percutaneous) use for skin, preferably, is prepared by formulating (A) macrolide(s) or analogue(s)/derivatives thereof, cyclosporine A or analogue(s)/derivative(s) thereof, having an immunosuppressive activity as the active ingredient, and (B) an oil, surfactant, perfume, anti-oxidant, UV light-absorber, coloring matter, alcohol, water, moisturizing agent, and/or thickening agent, if necessary. In gradient A is preferably **ascomycin**, FK506, and/or cyclosporine A. Combination of these ingredients affords an additive or synergistic effect on the inhibition agent photosensitivity. The daily dose of the above preparation is preferably 0.1 μ g- to 10mg-active ingredient/cm²-lesion. It is preferable to administrate the amount divides in 1-4 portions per day.
COPYRIGHT: (C)1998,JPO